AACR 2021 | CANOPY-A: canakinumab for resected NSCLC

Alex Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, gives an overview of the Phase III CANOPY-A trial (NCT03447769) investigating the safety and efficacy of canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancer (NSCLC). Canakinumab is a human monoclonal antibody therapy that targets interleukin-1 beta, and in this interview, Dr Spira describes the rationale for this trial-in-progress. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.